Human Immunodeficiency Virus | Current Treatment | EU5 | 2016
The HIV therapy market is growing as a result of the uptake of new premium-priced antiretroviral agents, particularly the latest single-tablet regimens (STRs) with improved side-effect profiles that place an emphasis on safety and tolerability. Our Current Treatment content provides deep insights drawn from a survey of 253 infectious disease specialists, internal medicine physicians, and general practitioners in the EU5 regarding the current and anticipated use of HIV regimens, including the recently approved STR Genvoya (elvitegravir/emtricitabine/tenofovir alafenamide/cobicistat), by capturing patient- and market-share data, current prescribing trends, and anticipated changes in prescribing and treatment behavior.
Related Market Assessment Reports
Report
Post-Traumatic Stress Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Post-Traumatic Stress Disorder (US)
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of…
Report
Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…
